FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP
666 FIFTH AVENUE, 31ST FLOOR
NEW YORK, NEW YORK 10103-3198
WWW.FULBRIGHT.COM

NORMAN D. HANSON
PARTNER
NHANSON@FULBRIGHT.COM

DIRECT DIAL: (212) 318-3168
TELEPHONE: (212) 318-3000
FACSIMILE: (212) 318-3400

August 11, 2003

VIA FACSIMILE 212-450-1555

Dr. Pär Olsson
Ludwig Institute for Cancer Research
605 Third Avenue
New York, NY 10158

Re: U.S. Patent Application No. 09/451,739
LUD 5615 (09905230)

Dear Pär:

Following our discussion on August 8, I've prepared and filed an amendment. A copy is attached.

I did add language to claim 80 to state that the claimed nucleic acid molecule encodes a cancer associated antigen.

I will let you know when we have anything further.

Very truly yours,

Norman D. Hanson

NDH/rle
Attach.

25325443.1

1643

LUD 5615 (09905230) - NDH

VIA FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the U.S. Patent and Trademark Office on August 12, 2003.

FULBRIGHT & JAWORSKI LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	:	Dirk Jager, et al.
Serial No.	:	09/451,739
Filed	:	November 30, 1999
For	:	ISOLATED NUCLEIC ACID MOLECULES ENCODING CANCER ASSOCIATED ANTIGENS, THE ANTIGENS PER SE, AND USES THEREOF
Group Art Unit	:	1643
Examiner	:	G. Nichol

August 12, 2003

Hon. Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 CFR §1.111

Sir:

This amendment is presented in response to the office action of May 14, 2003. Please amend this application as follows:

A. AMENDMENTS TO THE CLAIMS

E1

Claims 1-79 (Canceled).

Claim 80: (currently amended) An isolated nucleic acid molecule, the complimentary sequence of which hybridizes, under highly stringent conditions (aqueous buffer, 65°C) to ~~one of~~ the nucleotide sequences set forth in SEQ ID NO: ~~4, 8, or~~ 15, wherein said nucleic acid molecule encodes a cancer associated antigen.

RISK TO STIC

DATE: